Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.74 |
| ▸ | ESR1 known ✓ | P03372 | 10/20 | 0.61 |
| ▸ | ESR2 known ✓ | Q92731 | 3/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.53 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.53 |
| ▸ | IDH1 known ✓ | O75874 | 1/20 | 0.53 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL17164709 | 1.00 | KMT2A (0.74) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Citric Acid SCHEMBL18496135 | 0.89 | ESR1 (0.77) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Citric Acid SCHEMBL17164706 | 0.89 | ESR1 (0.77) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Citric Acid SCHEMBL17164692 | 0.86 | ESR1 (0.71) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Citric Acid SCHEMBL17164712 | 0.86 | ESR1 (0.71) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Clomiphene SCHEMBL20942789 | 0.85 | KDM4E (1.00) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Enclomiphene SCHEMBL220459 | 0.85 | KDM4E (1.00) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Clomiphene SCHEMBL220953 | 0.85 | KDM4E (1.00) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Clomiphene SCHEMBL27599894 | 0.85 | KDM4E (1.00) | KMT2AKDM4EMEN1CYP2D6LMNA | |
| Zuclomiphene SCHEMBL223472 | 0.85 | KDM4E (1.00) | KMT2AKDM4EMEN1CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4341283-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3551197-B1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230242936-A1 | DUAL PROMOTER SYSTEMS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230130938-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4149966-A1 | DUAL PROMOTER SYSTEMS | Seattle Children's Hospital (DBA Seattle Children's Research Institute) (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220411805-A1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2022-12-29 | — | — | US | disclosed |
| WO-2022241289-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A TRANSCRIPTION FACTOR AND A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20190248891-A1 | DRUG REGULATED TRANSGENE EXPRESSION | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2019-08-15 | — | — | US | disclosed |
| US-10266592-B2 | Drug regulated transgene expression | SEATTLE CHILDREN'S HOSPITAL (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190016776-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2019-01-17 | — | — | US | disclosed |
| EP-3402509-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (DBA Seattle Children's Research Institute) (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3331920-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Seattle Children's Hospital, dba Seattle Children's Research Institute (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017123548-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20170152297-A1 | DRUG REGULATED TRANSGENE EXPRESSION | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2017-06-01 | — | — | US | disclosed |
| WO-2017027291-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-3129399-A1 | DRUG RELATED TRANSGENE EXPRESSION | Seattle Children's Hospital, dba Seattle Children's Research Institute (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015157432-A1 | DRUG RELATED TRANSGENE EXPRESSION | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2015-10-15 | — | — | WO | disclosed |